Oppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying the January ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd October 15, 2015 9:52 AM Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMDOctober 14, 2015 12:44 PM Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular DystrophyOctober 14, 2015 12:43 PM BioMarin's (BMRN) Drisparsen Advisory Committee Meeting Set for Nov. 24 October 14, 2015 9:16 AM